Publications en collaboration avec des chercheurs de Hospital Clínico Universitario Lozano Blesa (27)

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

2020

  1. Breakthrough cancer pain: review and calls to action to improve its management

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1216-1226

2019

  1. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  2. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

  3. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)

    Lung Cancer, Vol. 135, pp. 161-168

2018

  1. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

2017

  1. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

    Clinical Lung Cancer, Vol. 18, Núm. 2, pp. 178-188.e4

2014

  1. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155

2012

  1. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum

    Lung Cancer, Vol. 76, Núm. 3, pp. 354-361

2010

  1. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

    Lung Cancer, Vol. 68, Núm. 3, pp. 491-497

  2. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Journal of Translational Medicine, Vol. 8

2009

  1. Lung cancer and treatment in elderly patients: The Achilles Study

    Lung Cancer, Vol. 66, Núm. 1, pp. 103-106

  2. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer

    Lung Cancer, Vol. 63, Núm. 1, pp. 83-87

  3. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967

  4. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

2008

  1. Pharmacogenetics in lung cancer for the lay doctor

    Targeted Oncology, Vol. 3, Núm. 3, pp. 161-171

2006

  1. Pharmacogenomics and gemcitabine

    Annals of Oncology, Vol. 17, Núm. SUPPL. 5

  2. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675

  3. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial

    Annals of Oncology, Vol. 17, Núm. 3, pp. 467-472

  4. The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer

    Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3